Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases - Wikidata - awgldk - TriplyDB

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

http://www.wikidata.org/entity/Q57693579

about

The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer Modeling somatic evolution in tumorigenesis Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer Evolution of cooperation among tumor cells Keystone symposium: the role of microenvironment in tumor induction and progression, Banff, Canada, 5-10 February 2005 Internet-based Profiler system as integrative framework to support translational research.The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer Clonal origin and spread of metastatic prostate cancer Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Persistent androgen receptor addiction in castration-resistant prostate cancer Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications Distinct genetic alterations in small cell carcinoma from different anatomic sites The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance Chemotherapy options in castration-resistant prostate cancer Using circulating tumor cells to inform on prostate cancer biology and clinical utility β-Adrenergic Receptor Signaling in Prostate Cancer The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cells Detection of patient subgroups with differential expression in omics data: a comprehensive comparison of univariate measures Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE)Metastasis: a therapeutic target for cancer.Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.Pro-neural transcription factors as cancer markers.Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis

P2860

Q21093318-A96EF1A0-6529-4D62-9AFD-4787D1EA9D38 Q21202034-E6E262E0-B2EE-4EFF-8A40-E1D51D5AF321 Q21563511-0E771A4D-605A-41E9-A8B8-CD7300A905D9 Q24337932-3EB85B4A-7FD3-4A13-BF72-AB9E921D5B22 Q24539093-C623A93E-3403-4B33-A369-871406C2BB26 Q24546102-93316BC8-6168-44C5-A54B-2CBF8228F591 Q24625643-A79B2AED-E81A-4DE6-AC8D-5DF0CD87FE42 Q24650647-7109F394-A1E1-48E4-B987-49FB16D081A4 Q24671009-ACA79A0A-545B-4E69-8561-44414D0398F3 Q24810275-89B2ECC0-2C14-4F99-AE2B-8B62D0024227 Q25257221-FA7D819E-8C26-4D74-8683-4CED6903337E Q26738703-079BE381-AF82-4284-97BA-19D8EF42540C Q26752873-44A7033C-76FC-46E4-B4F2-7CFB66C5B457 Q26773634-F579CCEB-F417-4CAE-A528-A7DA4B5F4999 Q26777163-BF54A94D-B568-41DD-8F09-19971A423975 Q26777310-ED4E7BA6-8D80-4611-BCD0-98B2BDC002F2 Q26797063-712CA2DB-76E2-40B8-A1B4-5AE066DF87C1 Q27008242-C464D016-1F53-443F-AF08-B29363D0A6C8 Q28076745-E712274A-B364-4617-ACD7-C1C21D9C614D Q28078477-F43A3A40-A49F-4D39-98FA-9501C247744A Q28083261-58F993CF-EFB5-4394-B89D-3666833BBFC0 Q28084943-E6AE5180-C8D9-45CF-BD12-481E66E32C8C Q28118861-2113C7FF-0B65-42F8-85C5-B04E48905D09 Q28535386-224B54DF-C23E-46C7-A631-CF5DEC46AC69 Q28593008-1B4C3784-06F4-4030-BDC2-48E82982A9BA Q28652074-77101FD8-6861-453F-9B98-72684A630CBA Q30439221-4BEA7F63-1F50-45AB-92D4-A982F5B4F375 Q30479181-C2CED681-F60E-4263-B457-AD3CACD2EE2B Q30482634-976BD3CC-D589-4148-B260-3A618D944DB6 Q30499412-65C6895E-DEC3-4BDA-AEFF-905A8A57D48E Q30500080-E405AD9A-7054-4032-8068-9BEAA3BB1341 Q30643770-A9F51E94-2017-486C-943C-AB82C9457936 Q33246793-5DD36D50-AF83-4051-8935-AB86686B1589 Q33247276-99E60986-27E3-44B4-B9A3-AF6863607D0D Q33281964-D78DF18C-5169-4E12-A7C8-6746EA9CD12F Q33316388-6985A586-AD39-481A-910A-835C92B8DBFD Q33335942-868C4623-3ACD-4B79-84CC-C6CA7A0E1596 Q33397762-2323F6FD-BFA8-4824-B9BF-F442AD90BD2E Q33471057-A9EB8CF2-B33E-4FE9-85DD-D2F69AB93BDD Q33586771-75171F2F-5C07-4554-9CEA-824A0B4EDCDB

P2860

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

http://www.wikidata.org/entity/Q57693579

description

article

@en

im Dezember 2004 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2004

@uk

name

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

@en

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

@nl

type

label

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

@en

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

@nl

prefLabel

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

@en

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

@nl

P1433

Q57693579-D9753139-5BD8-44E7-9543-9BADF9716CC6

P1476

Q57693579-F375A647-3593-4297-9494-DB0BBC3CB176

P2093

Q57693579-1A361444-A6B3-49A5-A067-82378201FAAE

Q57693579-2F022490-EF91-4DC5-AB25-4562A1785991

Q57693579-3E6B4A3D-1DB0-4275-8BC2-270E0DF1282C

Q57693579-59B53169-40C2-422C-98A1-2F9D556D4A09

Q57693579-87B7B882-2B1B-4654-8772-02EEE9104DD5

Q57693579-99DEE45F-E538-430C-B71B-079370E457CB

Q57693579-9CDED400-D94A-49FF-8627-975393DF122E

Q57693579-B1B01DFF-2384-4A27-8B83-7AE25930D0E5

Q57693579-C89FC203-380B-4ACA-A262-40D9AC4A637A

Q57693579-ECC0CFA1-923F-448E-BA89-0D21EA7AB601

P304

Q57693579-0035CA83-C9A8-4FC2-BA45-5049711A04C1

P31

Q57693579-1EFC4F11-3686-4AB4-8D5F-4421F38EAA08

P356

Q57693579-78DF3C5A-AF7B-477E-84BF-DCB088933A4A

P407

Q57693579-2F2B67C3-A595-4FF9-A3D1-A0DA67F921F1

P433

Q57693579-9442596E-F2F8-485D-BCD3-A7138EEDF958

P478

Q57693579-060790B8-36D4-4657-BB6A-52725F86C798

P50

Q57693579-1387B52D-2E4D-41BF-A91A-D76B9B55A566

Q57693579-B3AC9AB5-8EF3-4C09-BFA7-0AA2304BDF2D

Q57693579-D1D81983-1D98-4673-BF15-93D7B14EFF55

P577

Q57693579-47C01950-E2E4-4FD4-938F-61BA80EE3B15

P698

Q57693579-55D405CB-B6B8-4B74-A10B-78E8AAC8D64D

P356

0008-5472.CAN-04-2442

P1433

Cancer Research

P1476

Androgen-independent prostate ...... s from a rapid autopsy program

@en

P2093

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Debashis Ghosh

http://www.w3.org/2001/XMLSchema#string

Gary R Macvicar

http://www.w3.org/2001/XMLSchema#string

Jason Harwood

http://www.w3.org/2001/XMLSchema#string

Ming Zhou

http://www.w3.org/2001/XMLSchema#string

Rajal B Shah

http://www.w3.org/2001/XMLSchema#string

Robert Kim

http://www.w3.org/2001/XMLSchema#string

Rohit Mehra

http://www.w3.org/2001/XMLSchema#string

Ronglai Shen

http://www.w3.org/2001/XMLSchema#string

Tarek A Bismar

http://www.w3.org/2001/XMLSchema#string

P304

9209-9216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-04-2442

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Sooryanarayana Varambally

Kenneth J. Pienta

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15604294

http://www.w3.org/2001/XMLSchema#string